PharmaSmart, PDX technology integrate through new partnership
FORT WORTH, Texas — PharmaSmart’s kiosks will be integrated with PDX’s Enterprise Pharmacy System, allowing pharmacies with the EPS system to collect data from patients through the kiosks, under a partnership between the two companies announced Friday.
When patients opt-in, such clinical data as blood pressure and weight from the kiosks are recorded to their records in EPS and then to their centralized healthcare records stored in the Rx.com Enterprise Pharmacy Record. The integration will also allow notification of pharmacy staff when severe or urgent lab data indicate that intervention is required. The technology will be available in EPS in 2014, the companies said.
"PDX understands that pharmacies need tools to not only remain competitive in the marketplace, but also to drive patient outcomes," PDX president Brad Crosslin said. "By integrating this type of technology with EPS and facilitating the collection of clinical data within the patient’s healthcare record at the pharmacy and within the national [Enterprise Pharmacy Record], we are helping pharmacists take an even more thorough, direct role in the care of their patients."
Patients using the kiosk receive a smart card that links them to their individual PharmaSmart profile, and the integration of the two systems will give pharmacists access to an advanced clinical portal providing a comprehensive overview of the patient’s historical biometric data. This allows timely patient interventions, counseling sessions and increases medication therapy management and cognitive healthcare assessments for hypertensive, obese and diabetic patients.
Amneal to launch generic contraceptive
BRIDGEWATER, N.J. — Generic drug maker Amneal Pharmaceuticals will launch its version of a contraceptive product at the beginning of January, the drug maker said.
Amneal said it would launch its version of 24 Fe (norethindrone acetate and ethinyl estradiol tablets; ferrous fumarate tablets) in the 1 mg/20 mcg and 75 mg strength. As the first company to successfully file for Food and Drug Administration approval of the drug, Amneal’s product will have 180 days in which to compete exclusively against the branded version.
Loestrin 24 Fe had sales of $510.6 million during the 12-month period that ended in June 2013, according to IMS Health. The maker of branded Loestrin 24 Fe, Ireland-based Warner Chilcott, was acquired this year by Actavis.
Salix Pharmaceuticals to buy Santarus
RALEIGH, N.C. — Salix Pharmaceuticals will buy Santarus for $2.6 billion, the drug makers said.
Salix will acquire all outstanding common stock of Santarus for $32 in cash, representing an approximately 36% premium over the Wednesday closing price of the company. The acquisition is expected to close in first quarter 2014. Both companies specialize in gastrointestinal drugs.
"We are very pleased to be able to merge our sales forces, combine two complementary product portfolios, expand our pipeline, diversify revenue, access healthcare providers in primary care, add a significant number of healthcare prescribers to our called-on universe and to better position Salix for success in the present as well as the future," Salix president and CEO Carolyn Logan said. "Additionally, we look forward to all of our stakeholders — patients, healthcare providers, employees and stockholders — benefitting from the increased scale created by a larger, even stronger Salix."